Thirty-four RA subjects were studied, 18 receiving monotherapy with biological DMARDs based on TNF-α inhibitor and 16 with nonbiological DMARDs (9 patients were on methotrexate, 4 on chloroquine, and 3 on leflunomide). The gene discussed is TNF; the disease is rheumatoid arthritis.